Based on these results, Elacestrant (Orserdu) was granted FDA approval in 2023 for the management of advanced or metastatic BC in postmenopausal women who are ER-positive, HER2-negative, and have ESR1 mutations, following disease progression after at least one round of prior endocrine therapy. Here, ESR1 is linked to breast cancer.